A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

Inclusion Criteria

• •Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle-cell lymphoma (MCL), and is initiating ibrutinib therapy or has initiated ibrutinib therapy on or after 21 November 2014 (date of ibrutinib commercialization) for:
• •1. treatment of CLL/SLL in participants who have received at least 1 prior therapy; or
• •2. treatment in first line CLL/SLL participants in the presence of deletion (del) 17p or TP53 mutation in participants unsuitable for chemo-immunotherapy; or
• •3. treatment of participants with relapsed or refractory MCL
• •Not currently participating in another investigational study, clinical study, or any expanded access program at study entry
• •Has not participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program
• •Participant must sign a written informed consent form (ICF) allowing data collection and source data verification